Related Experiment Video
Updated: Jun 29, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Functional proteomic profiling of AML predicts response and survival
Steven M Kornblau1, Raoul Tibes, Yi Hua Qiu
1Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Blood
|October 9, 2008
Summary
This study developed a functional proteomic classification for acute myeloid leukemia (AML) by analyzing protein expression in 256 patients. Protein signatures identified distinct AML subtypes and correlated with prognosis, offering insights for targeted therapies.
Area of Science:
- Proteomics
- Cancer Biology
- Molecular Oncology
Background:
- Protein function is crucial for cancer phenotypes.
- A functional proteomic classification system can inform cancer pathogenesis and prognosis.
- Acute myeloid leukemia (AML) requires novel classification systems for improved patient outcomes.
Purpose of the Study:
- To develop a proteomic-based classification system for acute myeloid leukemia (AML).
- To identify distinct protein expression signatures in AML subtypes.
- To correlate proteomic patterns with clinical characteristics and patient prognosis.
Main Methods:
- Assayed 51 total and phosphoproteins from key cellular pathways in leukemia-enriched cells from 256 newly diagnosed AML patients.
- Utilized reverse-phase protein arrays for high-throughput protein expression analysis.
- Employed principal component analysis to define protein signature groups and assess prognostic value.
Main Results:
- Protein expression patterns in peripheral blood and bone marrow were largely similar.
- Identified distinct protein signatures for French-American-British (FAB) subtypes and specific cytogenetic abnormalities (e.g., -5/ -7, FMS-like tyrosine kinase 3-internal tandem duplication).
- Defined 7 protein signature groups with prognostic information independent of cytogenetics, correlating with remission, relapse, and survival.
Conclusions:
- Protein expression profiling in AML correlates with established morphologic features, cytogenetics, and clinical outcomes.
- Distinct proteomic signatures can differentiate AML subtypes and predict prognosis.
- Further validation may facilitate patient stratification for targeted therapies in AML.
